Related Experiment Video
Updated: Aug 3, 2026
Delivery of Modified mRNA in a Myocardial Infarction Mouse Model
Published on: June 11, 2020
Lidocaine Administration Controls MicroRNAs Alterations Observed After Lung Ischemia-Reperfusion Injury
Lisa Rancan1, Carlos Simón, Emmeline Marchal-Duval
1From the *Department of Biochemistry and Molecular Biology III, Faculty of Medicine, Complutense University of Madrid, Spain; Departments of †Thoracic Surgery and ‡Anesthesiology, Hospital Gregorio Marañón, Madrid, Spain; and Departments of §Physiology and ‖Biostatistics and Operational Investigation, Faculty of Medicine, Complutense University of Madrid, Spain.
Lung ischemia-reperfusion injury (IRI) alters microRNA (miRNA) expression. Lidocaine administration significantly reduced these miRNA changes, suggesting a therapeutic role in mitigating lung IRI.
Area of Science:
- Cardiovascular Science
- Pulmonary Medicine
- Molecular Biology
Background:
- Ischemia-reperfusion injury (IRI) is a significant cause of morbidity and mortality.
- MicroRNAs (miRNAs) are key regulators of IRI and organ rejection.
- Lidocaine's anti-inflammatory effects are known, but its impact on miRNA modulation in IRI is unexplored.
Purpose of the Study:
- To investigate miRNA involvement in lung IRI using a lung auto-transplantation model.
- To evaluate the therapeutic effect of lidocaine on miRNA dysregulation during lung IRI.
Main Methods:
- A lung auto-transplantation model in pigs (sham, control, lidocaine groups).
- Lung biopsies collected at multiple time points (pre-clamp, pre-reperfusion, 30, and 60 minutes post-reperfusion).
- Quantitative PCR analysis of 15 specific miRNAs, normalized to miR-103.
Main Results:
- Lung IRI significantly increased the expression of several miRNAs (miR-21, miR-107, miR-126, miR-145, miR-146a, miR-182, miR-192, miR-142-5p, miR-152, miR-155, miR-223) at 30 and 60 minutes post-reperfusion.
- Lidocaine administration significantly attenuated these IRI-induced miRNA alterations.
- miR-127 and miR-16 expression levels did not significantly increase post-IRI.
Conclusions:
- Lung IRI leads to significant miRNA dysregulation.
- Lidocaine effectively reduces miRNA alterations associated with lung IRI.
- These findings highlight lidocaine's potential as a therapeutic agent for lung IRI.
